dm+d
Unassigned
New Medicines
Non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis
Information
New molecular entity
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Dec 20Dec 20: PIII MAESTRO-NASH trial (NCT03900429) is ongoing with an estimated primary completion date of Dec 21 [5]
Category
First-in-class thyroid hormone receptor (THR) β-agonist, liver directed
Reported prevalence varies widely depending on country, definition and diagnostic method used, however the prevalence of NASH in Europe is considered to be around 5% [3].
Non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis
Oral